DHL Wins Best Logistics & Supply Chain Management Supplier Award at IMAPAC Asia Pacific Biopharma Excellence Awards (ABEA) 2026

DHL has been recognized as the Best Logistics & Supply Chain Management Supplier under the Asia's 3PL Excellence category at the Asia‑Pacific Biopharma Excellence Awards (ABEA). Now in its 10th edition, the ABEA is organised by IMAPAC, a leading biopharma-focused events and intelligence company, to celebrate outstanding achievements and innovations across the region’s biopharma value chain. Winners are determined through voting by biopharma professionals in the region via a shortlist informed by IMAPAC’s market research and recent sector developments.

Strengthening life science and healthcare supply chains across Asia Pacific

The Asia Pacific healthcare cold chain logistics market is forecast to expand the next few years and reach USD 42.5 billion by 2031. DHL is bolstering its capabilities to deliver integrated, faster, more reliable, and patient-centric logistics solutions for the Life Sciences & Healthcare (LSH) sector under DHL Health Logistics, the Group’s global brand for pharmaceuticals, medical devices, biopharma, and clinical trials. Today, the DHL global network connects over 220 countries and territories globally, supported by more than 250 Good Distribution Practice (GDP)‑qualified warehouses in 43 countries. In February 2026, DHL expanded its dedicated Airfreight Cold Chain Network, with upcoming lanes planned for Asia, including Singapore.

In addition, the Group announced a strategic investment of €2 billion in April 2025 to accelerate its logistics capabilities globally, of which €500 million will go towards Asia Pacific to develop GDP-certified pharma hubs, cold-chain capacity, specialized last mile vehicles, and end-to-end visibility systems. Besides DHL’s Worldwide Medical Express (WMX), a specialised shipping solution designed for urgent deliveries of time and temperature-sensitive shipments, DHL has also acquired CRYOPDP, a leading specialty courier providing white-glove, temperature-controlled logistics for the pharmaceutical, biopharmaceutical, and advanced therapy sectors to sharpen its capabilities in specialty pharma logistics.

Building Singapore as a health logistics hub

As a key hub in the region’s network, DHL continues to scale its LSH capabilities in Singapore to drive growth and supply chain resilience in this sector. Its new €10 million Pharma Hub launched in 2025 is fitted with 8,200 m² of GDP/Good Manufacturing Practice (GMP)‑compliant space with ambient (15 - 25°C) and cold‑room (2 - 8°C) zones - and is strategically linked to Changi Airport and Tuas Mega Port to serve regional and global distribution needs.

Christopher Ong, Managing Director, DHL Express Singapore says: “This award is a vote of confidence from the biopharma community and a proud moment for us at DHL. Across Singapore and APAC, we are deepening our capabilities in healthcare logistics so that critical medicines and advanced therapies reach patients safely, on time and in the right condition. We are committed to strengthening our infrastructure, temperature-controlled expertise, and real-time visibility to enhance reliability in lifesaving deliveries.”

Eunis Hew, Managing Director, DHL Supply Chain Singapore says: “This recognition from the biopharma community underscores the trust placed in DHL to safeguard critical healthcare supply chains. As therapies become more specialized and temperature-sensitive, reliability and end-to-end visibility are essential. Alongside investments such as the launch of our Pharma Hub in Singapore, we continue strengthening our capabilities through specialised expertise, GDP-compliant processes, and trained healthcare logistics professionals to support biopharma customers across the region.”

“Singapore continues to strengthen its position as a strategic hub for Life Sciences and Healthcare logistics. This recognition from industry professionals reaffirms our role in supporting the sector’s dynamic growth and rising demand for seamless cold chain solutions. Equally, biopharma businesses rightly expect that their products to be handled with precision and care. This is why our investments in Singapore – from GDP-certified infrastructure to real-time monitoring technologies and dedicated cold chain airfreight lanes – are designed to deliver an unbroken, end-to-end cold chain. Our priority is ensuring that every shipment maintains its integrity, so patients across the region receive critical treatments safely and on time,” adds Praveen Gregory, Managing Director, DHL Global Forwarding Singapore & Malaysia.

To learn more about DHL Health Logistics, you can visit Life Sciences & Healthcare Logistics - DHL - Singapore.